The Nevada Cancer Research Foundation (NCRF) was established in 1983 to conduct cancer research under the National Cancer Institute's (NCI), Community Clinical Oncology Program (CCOP) grant. The NCRF main office is located in central Las Vegas with satellite offices in Reno and Carson City, Nevada. The NCRF's mission is to provide high-quality, state-of-the-art, cancer treatment and cancer control and prevention research to the citizens of Nevada through the participation of the local physicians and health care providers at their facilities. The NCRF also has as part of its mission the provision of high quality, timely data to the Research Bases in a research environment that sets the highest standards for the safety and welfare of the clinical trials participants. The long-term NCRF-CCOP grant objectives have been and continue to be: 1) to accrue a minimum of 50 participants annually to NCI-approved cancer treatment clinical trials in Nevada;2) to accrue a minimum of 50 participants annually to NCI-approved cancer control and prevention studies in Nevada;3) to provide timely data of high quality to the Research Bases;4) to promote quality and state-of-the-art treatment in the community through participation in clinical trials by (a) involving NCRF-CCOP physicians and staff in scientific and educational activities of the Research Bases;(b) expanding the knowledge, awareness, and involvement of the primary healthcare providers and specialists in the Research Base activities for the development and use of cancer prevention and control research;5) to support other professional education programs and cancer prevention and control outreach services to under-served rural areas;6) to identify women and minority groups that may be underserved and to involve them in clinical trials;and 7) to continue to with the NCI to develop a community cancer network in order to facilitate the growth, development, and implementation of important new cancer initiatives. To accomplish these goals, the NCRF-CCOP makes the program available to all interested professionals from varied medical disciplines for state-wide participation, thereby providing access for participation to the citizens of Nevada.

Public Health Relevance

This state-wide program provides access to new cancer treatment and prevention programs as well as providing access to symptom management, quality of life and biology studies for the citizens of Nevada.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035421-30
Application #
8511574
Study Section
Special Emphasis Panel (ZCA1-SRLB-E (J1))
Program Officer
Whitman, Cynthia B
Project Start
1983-09-30
Project End
2015-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
30
Fiscal Year
2013
Total Cost
$427,060
Indirect Cost
$245,115
Name
Southern Nevada Cancer Research Fdn
Department
Type
DUNS #
173852054
City
Las Vegas
State
NV
Country
United States
Zip Code
89106
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-40
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43

Showing the most recent 10 out of 54 publications